FDA Approved: ZILRETTA — Supplemental Application (Pacira Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves a supplemental application for ZILRETTA, an extended-release intra-articular corticosteroid, submitted by Pacira Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• ZILRETTA (Triamcinolone acetonide extended-release injectable suspension)

Snippet

SUPPL AP for ZILRETTA (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION)